# RE104 Radiolabeled Mass Balance (hAME) Study

> **NCT07146191** · PHASE1 · COMPLETED · sponsor: **Reunion Neuroscience Inc** · enrollment: 8 (actual)

## Conditions studied

- Healthy Participant Study

## Interventions

- **DRUG:** 2-[14C]-RE104 for Injection

## Key facts

- **NCT ID:** NCT07146191
- **Lead sponsor:** Reunion Neuroscience Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-19
- **Primary completion:** 2025-10-02
- **Final completion:** 2025-10-02
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07146191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07146191, "RE104 Radiolabeled Mass Balance (hAME) Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07146191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*